RVMD - Revolution Medicines, Inc.

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that members of Revolution Medicines' senior management team will host a webcast on Sunday, May 31 at 7:00 pm ET to discuss positive results from the Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) following presentation of the data during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

May 21, 2026 12:05 PM • globenewswire.com

GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks

GraniteShares has filed with the U.S. Securities and Exchange Commission to launch three new leveraged single-stock ETFs tied to high-volatility themes spanning nuclear energy, AI infrastructure and biotech.

May 19, 2026 05:50 AM • benzinga.com

Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report

U.S. cancer centers are moving quickly to enroll patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ:RVMD) after clinical trial results showed the treatment significantly extended survival in patients with advanced disease.

May 15, 2026 07:47 AM • benzinga.com

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from ​Revolution Medicines while they await what they hope will be a speedy FDA approval.

May 14, 2026 02:04 AM • reuters.com

Small-Cap ETF Showdown: Schwab's SCHA vs. iShares' IJR

Expense ratios, diversification, and sector tilts set these two small-cap ETFs apart. Explore how their strategies impact risk and long-term performance.

May 11, 2026 07:13 AM • fool.com

RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View

Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.

May 07, 2026 09:50 AM • zacks.com

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer

May 06, 2026 02:00 PM • globenewswire.com

Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects

An experimental drug from Revolution Medicines that nearly ​doubled survival time for patients with advanced pancreas cancer in clinical trials comes with a high rate ‌of mostly low-grade side effects, researchers reported on Wednesday.

May 06, 2026 01:01 PM • reuters.com

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation RASolute 302 data planned for submission to global regulatory authorities, including the U.S. Food and Drug Administration AACR 2026 presentations reinforce the breadth and strength of company's RAS(ON) portfolio, highlighting continued progress and novel approaches to RAS(ON) inhibition Strengthened financial position with financings totaling $2.2 billion in gross proceeds Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif.

May 06, 2026 12:02 PM • globenewswire.com

US FDA authorizes early access to Revolution's pancreatic cancer pill

The U.S. Food and Drug Administration has authorized the granting of early access before regulatory approval to Revolution ​Medicines' pill for patients with previously treated ‌pancreatic cancer, the company said on Friday.

May 01, 2026 08:54 AM • reuters.com

Which Is the Better Small-Cap ETF, Vanguard's VB or iShares' ISCB?

Compare how sector allocations, cost, and diversification set these two leading small-cap ETFs apart for investors seeking broad market exposure.

May 01, 2026 05:06 AM • fool.com

Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, after market close.

Apr 29, 2026 12:05 PM • globenewswire.com

Vanguard vs. Schwab: Which Small-Cap ETF Belongs in Your Portfolio?

Expense ratios, diversification, and recent returns reveal key differences between these two leading small-cap ETFs.

Apr 29, 2026 09:08 AM • fool.com

Schwab Small Cap ETF Tops State Street in Returns and Diversification

Compare how expense ratios, yield, and portfolio breadth set these two small-cap ETFs apart in risk and income profile.

Apr 29, 2026 07:27 AM • fool.com

There's a Revolution in Cancer. But Can Big Pharma Afford It?

Revolution Medicines' stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking unlikely, investors should be prepared for the long haul.

Apr 28, 2026 01:30 AM • wsj.com

Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems

Investors have grown excited about Revolution Medicines due to its promising pancreatic cancer drug, daraxonrasib. Daraxonrasib significantly extended the life of patients in a recent clinical trial.

Apr 27, 2026 07:00 AM • fool.com

SPSM Offers Lower Costs and Higher Yield Than ISCB

Explore how these two small-cap ETFs differ in diversification, risk, and portfolio strategy to help refine your investment approach.

Apr 24, 2026 06:50 AM • fool.com

Two experimental drugs showed striking early results against pancreatic cancer

Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.

Apr 21, 2026 01:35 PM • wsj.com

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data from two Phase 1/2 trials of daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). Data from the daraxonrasib combination cohort will be presented in a late-breaking mini-symposium, and data from the monotherapy cohort will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting on April 21, 2026.

Apr 21, 2026 01:35 PM • globenewswire.com

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer

Apr 21, 2026 01:30 PM • globenewswire.com

Revolution Medicines initiated with a Market Perform at Bernstein

$151.00 (was $153.73)

Jeffrey Walch · Bernstein

May 21, 2026 04:24 PM • TheFly

Revolution Medicines assumed with a Buy at Truist

$179.00 (was $145.66)

Truist Financial

May 18, 2026 06:23 AM • TheFly

Revolution Medicines price target raised to $205 from $175 at Guggenheim

$205.00 (was $151.07)

Guggenheim

May 07, 2026 06:40 AM • TheFly

Revolution Medicines price target raised to $175 from $160 at Guggenheim

$175.00 (was $136.30)

Guggenheim

Apr 14, 2026 07:45 AM • TheFly

Revolution Medicines price target raised to $200 from $140 at Evercore ISI

$200.00 (was $136.30)

Evercore ISI

Apr 14, 2026 07:38 AM • TheFly

Revolution Medicines price target raised to $162 from $140 at RBC Capital

$162.00 (was $136.30)

RBC Capital

Apr 14, 2026 07:06 AM • TheFly

Revolution Medicines price target raised to $169 from $73 at H.C. Wainwright

$169.00 (was $136.30)

Robert Burns · H.C. Wainwright

Apr 14, 2026 06:10 AM • TheFly

Revolution Medicines price target raised to $165 from $150 at Oppenheimer

$165.00 (was $134.88)

Oppenheimer

Apr 13, 2026 11:45 AM • TheFly

Revolution (RVMD) PT Raised to $144 at Wells Fargo

$144.00 (was $103.24)

Eva Fortea Verdejo · Wells Fargo

Feb 26, 2026 06:00 AM • StreetInsider

Revolution Medicines price target raised to $150 from $75 at Oppenheimer

$150.00 (was $97.78)

Jay Olson · Oppenheimer

Jan 27, 2026 07:50 AM • TheFly

Revolution Medicines price target raised to $170 from $85 at Stifel

$170.00 (was $117.84)

UBS

Jan 22, 2026 08:32 AM • TheFly

Revolution Medicines price target raised to $140 from $77 at RBC Capital

$140.00 (was $116.22)

Leonid Timashev · RBC Capital

Jan 21, 2026 06:37 AM • TheFly

Revolution Medicines price target raised to $160 from $92 at Guggenheim

$160.00 (was $120.28)

Guggenheim

Jan 20, 2026 07:19 AM • TheFly

Goldman Sachs on Revolution (RVMD): 'Catalyst-rich 2026 underpins the breadth of the clinical portfolio'

$73.00 (was $119.95)

Andrea Newkirk · Goldman Sachs

Jan 13, 2026 09:07 AM • StreetInsider

Revolution Medicines price target raised to $143 from $90 at Mizuho

$143.00 (was $117.17)

Mizuho Securities

Jan 13, 2026 06:58 AM • TheFly

Revolution Medicines price target raised to $147 from $80 at Wedbush

$147.00 (was $112.68)

Wedbush

Jan 09, 2026 08:38 AM • TheFly

RBC Capital Starts Revolution (RVMD) at Outperform

$77.00 (was $58.84)

Leonid Timashev · RBC Capital

Nov 03, 2025 02:16 AM • StreetInsider

Revolution Medicines price target raised to $80 from $78 at BofA

$80.00 (was $53.81)

Alex Stranahan · National Bank

Oct 17, 2025 09:32 AM • TheFly

Revolution Medicines price target raised to $76 from $72 at Raymond James

$76.00 (was $49.68)

Raymond James

Oct 17, 2025 08:07 AM • TheFly

Revolution Medicines resumed with a Buy at Stifel

$85.00 (was $49.56)

Stifel Nicolaus

Oct 15, 2025 04:30 PM • TheFly